

### PHIRI Use Cases – measuring the impact of COVID-19 on population health

Enrique Bernal-Delgado, IACS, ES Martin Thissen, RKI, DE



www.phiri.eu



This project has received unding from the European Jnion's Horizon 2020 esearch and innovation programme under grant greement No 101018317

### **Research Use Cases on COVID-19 – Objectives**

4 real life research use cases measuring the impact of COVID-19 on population health

www.phiri.eu



5

ROBERT KOCH INSTITUT

Direct and indirect determinants of COVID-19 infection and outcomes in vulnerable population groups with reference to inequalities

÷

COVID-19 related delayed care in breast cancer patients

The impact of COVID-19 on perinatal health and perinatal health inequalities

IACS Instituto Aragonés de Ciencias de la Salud

COVID-19 related changes in population mental health

**Demonstrate** how a broad variety of data (e.g. administrative and survey data) can be reused in a distributed way across Europe:

- a) Conduct research through use cases of immediate relevance on the consequences of the COVID-19 pandemic on European population health
- b) Pilot activities for the benefits and added value of a federated research infrastructure by bringing together data from different European countries





Has the COVID19 pandemic changed existing patterns of non-COVID-19 health care utilisation for (vulnerable) populations within and between countries?

- Heart attack and strokes (Cohort 1)
- Hip and knee replacements (Cohort 2)
- Serious trauma admissions (Cohort 3)

	Associated entity in ERD	Label (var_label)	Name (var_concept)	Classification/Encoding	Units	Format	Description
	patient	patient_id	patient identificator	private key ciphering function	none	string	patient pseudonymized identificator
hasiaa	patient	sex	sex				
Dasics	patient	age_nm	age	none	years	integer	patient's age as of 2019-01-01
	observation period	period	[time period]	none	month	integer	natural month
	heart event	acute_event_heart	major vascular event - heart attack	ICD10:I21			
ophort 1	date heart event	date_event_heart	date - heart attack	date	date_DMY_nr	YYYY-mm-dd	
Conort	stroke event	acute event stroke	major vascular event - stroke	160-164			
	date stroke event	date event stroke	date - stroke		date_DMY_nr	YYYY-mm-dd	
	procedure	ttm type cd	type of treatment	types of treatment referred	none	integer	type of treatment received by the patient
cohort 2	procedure	surgery_elective_hip	elective surgery, hip joint replacement	OPCS codes in UK W37-W39			
	procedure	surgery elective knee	elective surgery, knee joint replacement	OPCS codes in UK W40-W42			
cohort 3	condition	acute_event_trauma	hospital admission for trauma based on	ICD10: S720, S721, S722, S723,	none	string	Based on scientific analysis by New
	Date of event	date_event	date of admission	date	date_DMY_nr	YYYY-mm-dd	date of admission
	Optional:						
	patient	educ_cd	highest completed education level	quintile or top/bottom	quintiles	integer	patient's highest completed education
	patient	socecon_lvl_cd	socioeconomic level	quintile or top/bottom	quintiles	integer	patient's socioeconomic level (quintile)
optional	patient	country_cd	country (residence)	ISO3166	none	string	patient's country of residence
	patient	district_cd	district (residence)	e.g. Eurostat NUTS			
	patient	country_origin_cd	country (origin)	ISO3166	none	string	patients' country of origin (country of







This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101018317

3





IACS Instituto Aragonés de Ciencias de la Salud

www.phiri.eu



IACS Instituto Aragonés de Ciencias de la Salud

**ROBERT KOCH INSTITUT** 

European age-standardised rates (solid lines) and the 95% CI (shaded area) across four selected forms of HCU in six European regions.



n nt 317

www.phiri.eu



Was there any delay in the treatment of breast cancer patients associated with the COVID-19 pandemic?

**Data hubs participation:** N = 4 <u>Aragon</u> (AR, Spain), <u>Wales</u> (WA, United Kingdom), <u>Belgium</u> (BE), <u>Marche</u> (MA, Italy)

🕀 💿 🌔 🕕





\* \* This project has received funding from the European \* \* \* \* Union's Horizon 2020 research and innovation programme under grant agreement No 101018317



Were population indicators of maternal and newborn health affected by the pandemic/lockdown?

#### Stillbirth (baby born without signs of life)

- 3-4 per 1000 births (15-18,000 babies per year in Europe)
- High health and psychological burden for parents, costs for families and society

#### Preterm birth (birth before 37 weeks of gestation)

- Affects about 350,000 births per year in Europe, few effective prevention strategies
- Principal cause of infant death
- Long-term neurodevelopment impairment and other health problems among survivors



www.phiri.eu



www.phiri.eu



IACS Instituto Aragonés de Ciencias de la Salud

**Pooled estimate** RR=0.96 (0.96 to 0.98) = 4% decrease in preterm birth

#### **High heterogeneity**

 $I^2 = 77.5\%$  (proportion of total variation in effect estimate due to between-study heterogeneity)

**Range of effects** = 10% decrease in preterm birth to moderate increase of 3 to 4%.

Countries with stronger effects: Portugal -Belgium – UK – Spain – Italy – France

Countries with no effects: Nordic and Baltic countries, Netherlands



**Estimate of pooled effect** RR=1.05 (1.02 to 1.08) = 5% increase in stillbirth

Lower heterogeneity

 $I^2 = 20.3\%$  (proportion of total variation in effect estimate due to between-study heterogeneity)

**Range of effects** = No decreases significant / Austria higher stillbirth rates





IACS Instituto Aragonés de Ciencias de la Salud

www.phiri.eu







Has the mental health status (depression/anxiety) of the general population changed during the COVID-19 pandemic?

#### Table 3: Proportion of respondents reporting having negative feelings by age and gender, EU27 (%)

			Summer 2020			Spring 2021	
		Tense	Lonely	Depressed	Tense	Lonely	Depressed
	18–34 years	34	25	21	46	35	34
Men	35–49 years	30	21	19	41	31	32
	50+ years	22	18	15	28	26	23
	18–34 years	45	30	28	52	38	40
Women	35–49 years	38	22	27	49	34	39
	50+ years	24	18	17	35	30	29

Notes: Green = lowest value, red = highest value. All differences between the two time periods are statistically significant. Any discrepancies between the figures in the text and table are due to rounding.

Source: Living, working and COVID-19 e-survey data. Mental health and trust decline across EU as pandemic enters another year. EuroFound, 2021.



Results from 7 data hubs:

- Aragon (IACS)
- Austria
- Croatia
- Estonia •
- Finland •
- Romania
- Wales





Inion's Horizon 2020 search and innovatio

www.phiri.eu

#### Diagnoses of depression or anxiety



### **Research Use Cases on COVID-19 – Achievements**





What do population health researchers need to reuse sensitive individual level data? How can the PHIRI federated approach help?

Enrique Bernal-Delgado, IACS, ES Martin Thissen, RKI, DE

> DIPoH Distributed Infrastructure on Population Health



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement. No 101018317

### The issue

## ... when reusing data, particularly RWD, from multiple sites and multiple datasets

- Uneven data management capacity
- Poor harmonisation in data collection
- Poor standardisation in curation
- Poor datasets integration
- Quality issues in reuse
- Legal & ethical requisites purpose, minimisation
- DPO sensitivity risk aversion to reuse
- Uneven technical skills

### The approach

- Data-visiting principle "code meets data"
- Strict methodological workflow (LOST)



Computational architecture



### The principles

- Research Question
- Secondary use
- Sensitive Health Data
- Common Data Model (CDM)
- Security & privacy by design
- Enabling **rapid-cycle** analyses
- Aligned with HealthData@EU

### Federated

- **Open source** (software/stack)
- FAIR (stemming from R to F)
- Literate statistical programming
- Usability (easy-to-use interfaces)
- Aligned with advances towards
  Federated Learning

### **Federated architecture**



# Federated, secondary use, "codes meets data" strong reliance on interoperability



### Strict workflow enabling LOST interoperability







										consequence of the COVID19 crisis?	ant cancer, as a
										**Cohort description.** Women, 18 years old or older, with a first diagnosis of breast cancer b until today	etween 2017-01-01
Data model entity Associated entity in ERD	Label (var_label)	Name (var_concept)	Level (required/recommende d/optional)	Variable Classification/Encoding	Units	Format	Description	Data Quality References to validation rules	ETL Transformation at or	amm nouty; *findinidual level data is required ** **Common data model** includes variables on: patient identificator ae	
patient	patient_id	patient identificator	required	private key ciphering function	none	string	patient pseudonymized identificator	SHA256	double hash function a following SHA256 prote (see patient cohort defi in next sheet)	socioeconomic level country (residence) country (residence) type of treatment [surgery, radiotherapy, chemotherapy, instanton of several] time rat first saverary (dava)	y, hormonotherapy or
patient	age_nm	age	required	none	years	integer	patient's age at the moment	3-digits; min 18; max 80	it might need to be calco from 'birth_dt'	time til first radiotherapy session] (days) (bine til first prescription/administration of a chemotherapy treatment (time til first prescription/administration of a inmanotherapy (a.k.a bio citaxi)	[] (days) logical) treatment]
patient	socecon_Ivl_cd	socioeconomic level	recommended	quintile	quintiles	integer	patient's socioeconomic level (quintile)	min 1; max 5	it might need to be calct from 'income_lvl' or approximated through a combination of 'education_lvl' and othe variables	Itime Birls prescription/atministration of a hormonotherapy treatme liteme period (memb) You can explore the Common Data Model specification at <u>Mtos//doc</u> /attendionetis/di/LKEbs/DataT22/mtRE5/22/UMA6_Anax6220 UK3A III Note that you can comment directly on the Common Data Model th Your comments on any issue regarding the data model will be much a	nt] (days) 5.0000k.com ISNs/edit?usp-sharin rough the link, ppriciated!
patient	country_cd	country (residence)	required	1503166	none	string	patient's country of residence	1503166-3	conformance with ISO3166	-3 field calculated at individual level	
patient	country_origin_cd	country (origin)	recommended	1503166	none	string	patients' country of origin	1503166-3	conformance with ISO3166	-3 field calculated at individual level	
procedure	ttm_type_cd	type of treatment	required	types of treatment referred below or a combination of them	none	integer	type of treatment received by the patient	values restricted to existing categories	calculated following treatme type definition (see definitions in next sheets)	nt field calculated at individual level	
procedure	time_dz_to_surgery_nm	[time til first surgery]	required	none	days	double	time from breast cancer diagnosis to first surgical procedure	no negative values allowed	it might be calculated as the difference between the date of the breast cancer diagno: and the first surgical procedure related to the breast cancer treatment (se definitions in next sheets)	: sis field calculated at individual level e	
procedure	time_dz_to_radiotherapy _nm	[time til first radiotherapy session]	required	none	days	double	time from breast cancer diagnosis to first radiotherapy session	no negative values allowed	it might be calculated as the difference between the date of the breast cancer diagno: and the first radiotherapy session (procedure) (see definitions in next sheets)	sis field calculated at individual level	
procedure	time_dz_to_chemothera pg_nm	[time til first prescription/administration of a chemotherapy treatment]	required	none	days	double	time from breast cancer diagnosis to first prescription/administration of a chemotherapy treatment	no negative values allowed	it might be calculated as the difference between the date of the breast cancer diagnor and the prescription/administration of chemotherapy treatment (see definitions in next sheets)	: is field calculated at individual level	
procedure	time_dx_to_inmunothera py_nm	(time til first prescription/administration of a inmunotherapy (a.k.a biological) treatment]	required	none	days	double	time from breast cancer diagnosis to first prescription/administration of a inmunotherapy treatment	no negative values allowed	calculated as the difference between the date of the bre cancer diagnosis and the prescription/administration of immunotherapy treatmen (see definitions in next sheets)	as field calculated at individual level t	
drug exposure	time_dx_to_hormonothe rapg_nm	[time til first prescription/administration of a hormonotherapy treatment]	required	none	days	double	time from breast cancer diagnosis to first prescription/administration of a hormonotherapy treatment	no negative values allowed	calculated as the difference between the date of the bre cancer diagnosis and the prescription/administration of hormonotherapy treatme (see definitions in next sheets)	as field calculated at individual level ent	
observation period	period	[time period]	required	none	month	integer	natural month	уууу-тт	calculated as the natural month in which each patien recieved any of the aforementioned types of treatment	t field calculated at aggregated level	

#### Population Health Information Population Health Information Research Infrastructure Use Case B - Delayed care in cancer

\*Research question \*\* Has there been any increase

patients This survey aims at mapping the availability of individual level data at each data hub answer the research question posed by the Use Case B.

### Synthetic dataset

A





	А	В	с	D	E	F	G	н	1	J K	L	м
1 p	atient_id	ttm_type_cd ag	e_nm	time_dx_to_surgery_nm	time_dx_to_radiotherapy_nm	time_dx_to_chemotherapy_nm	time_dx_to_hormonotherapy_nm	time_dx_to_immunotherapy_nm	period	socecon_lvl_cd country_c	d country_origin_cd	hospital_id
2	1	1	59	21	NA	NA	NA	4	1	L 0 ESP	ESP	20
3	2	2	60	13	15	NA	NA	6	21	L 0 ESP	ESP	27
4	3	2	54	53	2	NA	NA	104	20	0 ESP	ESP	68
5	4	5	51	6	3	3	NA	18	8	B 0 ESP	ESP	98
6	5	3	72	NA	NA	1	NA	33	11	L 0 ESP	ESP	67
7	6	2	59	1	C	NA	NA	13	17	7 0 ESP	ESP	89
8	7	4	52	1	NA	NA	10	21	17	7 0 ESP	ESP	90
9	8	2	67	0	17	NA	NA	0	10	0 ESP	ESP	45
10	9	5	51	28	41	C	NA	2	33	1 ESP	ESP	5
11	10	2	57	1	53	NA	NA	0	11	L 0 ESP	ESP	88
12	11	5	58	53	16	7	NA	96	19	0 ESP	ESP	68
13	12	4	49	4	NA	NA	10	15	22	2 0 ESP	ESP	57
14	13	4	36	20	NA	NA	6	3	12	2 0 ESP	ESP	16
15	14	1	52	19	NA	NA	NA	8	7	7 0 ESP	ESP	17
16	15	4	64	0	NA	NA	1	13	22	2 0 ESP	ESP	13
17	16	4	46	116	NA	NA	107	61	27	7 0 ESP	ESP	75
18	17	1	65	3	NA	NA	NA	7	5	5 0 ESP	ESP	80
19	18	5	50	5	2	4	NA	12	14	0 ESP	ESP	54
20	19	4	42	10	NA	NA	4	52	29	0 ESP	ESP	40
21	20	5	68	32	2	. 93	NA	0	2	0 ESP	ESP	33
22	21	2	51	0	14	NA	NA	0	31	L 0 ESP	ESP	39
23	22	3	54	NA	NA	14	NA	0	21	L 0 ESP	ESP	94
24	23	3	44	NA	NA	37	NA	4	22	2 1 ESP	ESP	12
25	24	4	61	76	NA	NA	222	33	31	L 0 ESP	ESP	16
26	25	4	71	0	NA	NA	0	6	9	9 1 ESP	ESP	51
27	26	2	70	2	0	NA	NA	15	20	0 ESP	ESP	3
28	27	1	67	38	NA	NA	NA	35	32	2 0 ESP	ESP	90
29	28	5	56	81	319	9	NA	81	20	0 0 ESP	ESP	69
30	29	4	58	4	NA	NA	5	37	6	5 0 ESP	ESP	50
31	30	1	52	91	NA	NA	NA	178	1	L 0 ESP	ESP	41
32	31	5	57	0	1	C	NA	1	10	0 ESP	ESP	38
33	32	3	57	NA	NA	C	NA	2	21	L 0 ESP	ESP	92
34	33	1	47	92	NA	NA	NA	0	10	0 ESP	ESP	89
35	34	2	75	12	30	NA	NA	7	12	2 0 ESP	ESP	42
36	35	3	55	NA	NA	9	NA	2	20	0 ESP	ESP	75
37	36	5	43	38	72	22	NA	6	18	B 0 ESP	ESP	67
38	37	2	44	76	59	NA	NA	0	29	0 ESP	ESP	66
39	38	2	55	11	15	NA	NA	0	20	0 ESP	ESP	87
4	) E	breast_cancer_	ttm_d	elays_synthe 🔶				•				
Listo												<b>=</b>
-												

PHIRI Federated Analysis Application (Docker)

### Data quality assessment

PHIRI Federated Analysis Application (Docker)

	CPHIR delayed_ttm_breast_cancer				Usin	g Pythoi	n's <b>Pandas Profili</b>	ng API
		Overview						
		Overview Warnings (13) Repr	roduction		Overview Warnings 13	Reproduction		
		Dataset statistics			country cd has constant value "E	SP*		Constant
		Number of variables		13	<pre>country_origin_cd has constant</pre>	value "ESP"		Constant
Quality		Number of observations		19356	time_dx_to_surgery_nm has 3909	(20.2%) missing values		Missing
Quality		Missing cells		42583	time_dx_to_radiotherapy_nm has	11585 (59.9%) missing values		Missing
Analysis		Missing cells (%)		16.9%	<pre>time_dx_to_hormonotherapy_nm h</pre>	as 15531 (80.2%) missing values	8	Missing
(scripts)				2.9 MiD	<pre>patient_id has unique values</pre>			Unique
		Total size in memory		3.0 WID	time_dx_to_surgery_nm has 1960	1 (10.1%) zeros		Zeros
		Average record size in memory		208.0 B	time_dx_to_chemotherapy_nm has	1653 (8.5%) zeros		Zeros
					time_dx_to_hormonotherapy_nm h	as 656 (3.4%) zeros		Zeros
					<pre>time_dx_to_immunotherapy_nm ha</pre>	s 3083 (15.9%) zeros		Zeros
		Variables			<pre>socecon_lvl_cd has 17421 (90.0)</pre>	%) zeros		Zoros
		patient id	Distinct	19356	Minimum	1	-	
		Real number (R₂₀)	Distinct (%)	100.0%	Maximum	19356		
		UNIQUE	Missing	0	Zeros	0		
			Missing (%)	0.0%	Zeros (%)	0.0%		
			Infinite	0	Negative	0		
			Infinite (%)	0.0%	Negative (%)	0.0%	5000 tono tono tono	

#### library(kableExtra) library(wrapr) library(plyr)

library(DBI) library(dplyr) library(htmlTable) library(magrittr) library(utils) library(tidyverse)

{r load\_libraries}

**Analytical workflows** 

PHIRI Federated Analysis Application (Docker)

Analysis

(scripts)

total\_per\_year22 <- df %>% filter(GA >= 22) %>% group\_by(year) %>% tally()

total per year24 <- df %>% filter(GA >= 24) %>% group by(year) %>% tally()

total per year28 <- df %>% filter(GA >= 28) %>% group by(year) %>% tally()

www.phiri.eu

```{r load data} con <- dbConnect(RSQLite::SQLite(), "/home/phiri/analysis-scripts/inputs/database/database.db")</pre> df <- dbReadTable(con, "perinatal health")</pre>

n per year22<-df %>% filter(GA >= 22, VITAL != 4, VITAL!= 1, VITAL !=99) %>% group by(year) %>% tally()

n per year24<-df %>% filter(GA >= 24, VITAL != 4, VITAL != 1, VITAL !=99) %>% group by(year) %>% tally()

n\_per\_year28<-df %>% filter(GA >= 28, VITAL != 4, VITAL != 1, VITAL !=99) %>% group\_by(year) %>% tally()

indicator names <- c()

n\_per\_year22\$indicator <- "aa\_22weeks"

n per year24\$indicator <- "ab 24weeks"

n per year28\$indicator <- "ac 28weeks"

### **Containerised solution ready for deployment**



PHIRI Federated Analysis Application (Docker)

### **Running local analyses and results devolution**

PHIRI Federated Analysis Application (Docker)





#### Search countries - Search Europe - Search trainings - Services - Glossary Contact HOME - SERVICES STYLE I - PHIRI DEMONSTRATORS

Do it yourself



#### **Others are using PHIRI**





# POPULATION Health Inform

Population Health Information Research Infrastructure

# Thank you for your attention

Enrique Bernal-Delgado, IACS, ES Martin Thissen, RKI, DE





www.phiri.eu



#### USE CASE A Vulnerable populations

Has the COVID19 pandemic changed existing patterns of non-COVID-19 health care utilisation and mortality for vulnerable populations within and between countries?

CHECK THE DATA MODEL HERE!

#### USE CASE B Delayed treatment in breast cancer

Has there been any increase in surgical and/or co-adjuvant (i.e. radiotherapy, chemotherapy, inmunotherapy) treatments delay in elegible women diagnosed of breast cancer, as a consequence of the COVID19 crisis?

CHECK THE DATA MODEL HERE!

#### USE CASE C Perinatal health

Focus on the indirect effects of the COVID-19 pandemic on maternal and newborn health with a focus on potential inequalities regarding non-deferrable healthcare needs and risks of adverse perinatal outcomes due to stress and social deprivation.

CHECK THE DATA MODEL HERE!

#### Application

PHIR

Population Health Informatio

Research Infrastructure

#### Data mapping

 Select the Use Case you want to participate in and introduce your data for analysis. Data should be extracted from your health information systems following the requirements and specifications of the data model of the use

#### General analysis

2) Select the Use Case you want to participate in and launch the analyses provided by the Use Case coordinators. Analyses scripts are open source and can be audited by anyone.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101018317



 $\mathbf{k}$ 

斧

1

лı

>\_



www.phiri.eu

#### Has there been any increase in individuals with mental health risk factors or mental disease, as a consequence

**USE CASE D** 

Mental health

health risk factors or mental disease, as a consequence of the COVID19 crisis? This case study will measure changes in population mental health and healthcare utilisation associated with the COVID-19 pandemic.

CHECK THE DATA MODEL HERE!



ROBERT KOCH INSTITUT



IACS Instituto Aragonés de Ciencias de la Salud

www.phiri.eu





www.phiri.eu





To participate in a use case, you select the use case you want to participate in using the 'Use Case Selector'. This informs the application of the rigth syntactic and quality assessments to perform on the input data to check compliance with the specific use case data model

#### File upload

ROBERT KOCH INSTITUT



IACS Instituto Aragonés de Ciencias de la Salud

www.phiri.eu





ROBERT KOCH INSTITUT

IACS Instituto Aragonés de Ciencias de la Salud

www.phiri.eu





The PHIRI app checks whether your input data syntacticaly complies with the specifications of the data model for the use case you selected before and if it does not comply, it produces an error log file with information on the registers (lines) and variables (columns) that are not compliant for you to check and correct

ROBERT KOCH INSTITUT

IACS Instituto Aragonés de Ciencias de la Salud

www.phiri.eu



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101018317





IACS Instituto Aragonés de Ciencias de la Salud





|    | General analysis                                                                                                                                                                                                                                     |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| /T | Use case selector                                                                                                                                                                                                                                    |
|    | Delayed tim breast cancer                                                                                                                                                                                                                            |
|    | Description of the analysis<br>Has there been any increase in surgical and/or co-adjuvant (i.e. radiotherapy, chemotherapy, inmunotherapy) treatments delay in elegible women<br>diagnosed of breast cancer, as a consequence of the COVID19 crisis? |
|    |                                                                                                                                                                                                                                                      |
|    | Analysis<br>Please, be aware that this process may take several minutes depending on the Use Case.                                                                                                                                                   |

Next step if there are no syntactic errors will be to 'Launch' the analysis. The PHIRI app automatically launches the Data Quality Analysis in the background upon mapping the data without errors but you have to explicitly launch the analysis.

As you can be participating in multiple use cases, the PHIRI app enables you to map several data inputs (one per use case) and select for which use case you want to launch the analysis. Use the 'Use case selector' in the 'General Analysis' tab to select the use case you want to run and click on the '<u>Launch</u>

analysis' button







e European 2020 novation ler grant 01018317



The 'Launch analysis' button will change to 'Process is running' while the analysis is running. The PHIRI app will produce several messages for you to know when the analysis are done or in case of an issue.







Use case

Delayed ttm breast cancer

www.phiri.eu

In any case, you can control the analysis process in the 'Process control' tab by 'killing/stopping' a process at any time – for instance, if a process takes to long.

Actions

۲

1-1 of 1

Rows per page

10

ROBERT KOCH INSTITUT

1

\*

1

лı

>\_



IACS Instituto Aragonés de Ciencias de la Salud

Active processes

Name

Analysis

Start time

14:34









This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101018317



#### General analysis

Use case selector

#### Description of the analysis

Has there been any increase in surgical and/or co-adjuvant (i.e. radiotherapy, chemotherapy, inmunotherapy) treatments delay in elegible women diagnosed of breast cancer, as a consequence of the COVID19 crisis?

#### Analysis

Please, be aware that this process may take several minutes depending on the Use Case.

Launch analysis

Once the analysis are done you can go to the 'Outputs retrieval' tab to check and download your outputs

ROBERT KOCH ..



14

\*

± ₪ ≻\_

> IACS Instituto Aragonés de Ciencias de la Salud









This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101018317



### **PHIRI Federated Analysis Application (Docker)**

- PHIRI app demo available at phiri.iacs.es
- Help-Desk
  - Technical/Implementation support:
    - To: <a href="mailto:festupinnan.iacs@aragon.es">festupinnan.iacs@aragon.es</a>

# THANKS!



www.phiri.eu





# Replicating a use case in a federated research infrastructure

### https://github.com/cienciadedatosysalud/tutorial\_cdmb\_EUPHA

#### https://github.com/cienciadedatosysalud/by-covid\_baseline-use-case\_EUPHA





European 2020 ovation r grant 1018317

www.phiri.eu